Adrenoreceptors and nitric oxide in the cardiovascular system

Frontiers in Physiology

Volumn 4 NOV, Issue , 2013, Pages

  Conti, Valeria ^a   Russomanno, Giusy ^a   Corbi, Graziamaria ^b   Izzo, Viviana ^a,c   Vecchione, Carmine ^a,d   Filippelli, Amelia ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b UNIVERSITY OF MOLISE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

Adrenoreceptors; Endothelium; Nebivolol; Nitric oxide; Vascular tone

Indexed keywords

ADRENERGIC RECEPTOR; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; CHLORTALIDONE; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LISINOPRIL; NEBIVOLOL; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO;

ADRENERGIC SYSTEM; ANTIOXIDANT ACTIVITY; BLOOD VESSEL TONE; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; EXERCISE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; VASOCONSTRICTION; VASODILATATION;

EID: 84889687012     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00321     Document Type: Review

References (120)

1. Augeri, A. L., Tsongalis, G. J., Van Heest, J. L., Maresh, C. M., Thompson, P. D., and Pescatello, L. S. (2009). The endothelial nitric oxide synthase -786 T>C polymorphism and the exercise-induced blood pressure and nitric oxide responses among men with elevated blood pressure. Atherosclerosis 204, e28-e34. doi: 10.1016/j.atherosclerosis.2008.12.015
2. Balligand, J. L. (1999). Regulation of cardiac beta-adrenergic response by nitric oxide. Cardiovasc. Res. 43, 607-620. doi: 10.1016/S0008-6363(99)00163-7
3. Balligand, J. L. (2009). beta(3)-Adrenoceptor stimulation on top of beta(1)-adrenoceptor blockade "Stop or Encore?." J. Am. Coll. Cardiol. 53, 1539-1542. doi: 10.1016/j.jacc.2009.01.048
4. Balligand, J. L., and Cannon, P. J. (1997). Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler. Thromb. Vasc. Biol. 17, 1846-1858. doi: 10.1161/01.ATV.17.10.1846
5. Balligand, J. L., Kelly, R. A., Marsden, P. A., Smith, T. W., and Michel, T. (1993). Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl. Acad. Sci. U.S.A. 90, 347-351. doi: 10.1073/pnas.90.1.347
6. Balligand, J. L., Kobzik, L., Han, X., Kaye, D. M., Belhassen, L., O'Hara, D. S., et al. (1995). Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J. Biol. Chem. 270, 14582-14586. doi: 10.1074/jbc.270.24.14582
7. Barudzic, N., Turjacanin-Pantelic, D., Zivkovic, V., Selakovic, D., Srejovic, I., Jakovljevic, J., et al. (2013). The effects of cyclooxygenase and nitric oxide synthase inhibition on oxidative stress in isolated rat heart. Mol. Cell. Biochem. 381, 301-11. doi: 10.1007/s11010-013-1712-9
8. Bauer, P. M., Fulton, D., Boo, Y. C., Sorescu, G. P., Kemp, B. E., Jo, H., et al. (2003). Compensatory phosphorylation and protein-protein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J. Biol. Chem. 278, 14841-14849. doi: 10.1074/jbc.M211926200
9. Benjafield, A. V., and Morris, B. J. (2000). Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am. J. Hypertens. 13, 994-998. doi: 10.1016/S0895-7061(00)00282-X
10. Berlan, M., Galitzky, J., and Montastruc, J. L. (1995). Beta 3-adrenoceptors in the cardiovascular system. Fundam. Clin. Pharmacol. 9, 234-239. doi: 10.1111/j.1472-8206.1995.tb00290.x
11. Bray, M. S., Krushkal, J., Li, L., Ferrell, R., Kardia, S., Sing, C. F., et al. (2000). Positional genomic analysis identifies the beta(2)-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 101, 2877-2882. doi: 10.1161/01.CIR.101.25.2877
12. Bredt, D. S., and Snyder, S. H. (1994). Nitric oxide, a physiological messenger molecule. Annu. Rev.Biochem. 63, 175-195. doi: 10.1146/annurev.bi.63.070194.001135
13. Brixius, K., Bloch, W., Pott, C., Napp, A., Krahwinkel, A., Ziskoven, C., et al. (2004). Mechanisms of beta 3-adrenoceptor-induced eNOS activation in right atrial and left ventricular human myocardium. Br. J. Pharmacol. 143, 1014-1022. doi: 10.1038/sj.bjp.0705983
14. Brush, J. E. Jr., Faxon, D. P., Salmon, S., Jacobs, A. K., and Ryan, T. J. (1992). Abnormal endothelium-dependent coronary vasomotion in hypertensive patients. J. Am. Coll. Cardiol. 9, 809-815. doi: 10.1016/0735-1097(92)90522-O
15. Buxton, B. F., Jones, C. R., Molenaar, P., and Summers, R. J. (1987). Characterization and autoradiographic localization of beta-adrenoceptor subtypes in human cardiac tissues. Br. J. Pharmacol. 92, 299-310. doi: 10.1111/j.1476-5381.1987.tb11324.x
16. Calvert, J. W., Condit, M. E., Aragón, J. P., Nicholson, C. K., Moody, B. F., Hood, R. L., et al. (2011). Exercise protects against myocardial ischemia-reperfusion injury via stimulation of ß(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ. Res. 108, 1448-1458. doi: 10.1161/CIRCRESAHA.111.241117
17. Cannavo, A., Rengo, G., Liccardo, D., Pagano, G., Zincarelli, C., De Angelis, M. C., et al. (2013a). ß1-Adrenergic Receptor and Sphingosine-1-Phosphate Receptor 1 (S1PR1) Reciprocal Downregulation Influences Cardiac Hypertrophic Response and Progression to Heart Failure: Protective Role of S1PR1 Cardiac Gene Therapy. Circulation 128, 1612-1622. doi: 10.1161/CIRCULATIONAHA.113.002659
18. Cannavo, A., Rengo, G., Liccardo, D., Pironti, G., Scimia, M. C., Scudiero, L., et al. (2013b). Prothymosin alpha protects cardiomyocytes against ischemia-induced apoptosis via preservation of Akt activation. Apoptosis 18, 1252-1261. doi: 10.1007/s10495-013-0876-9
19. Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M., et al. (2013a). Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. 62, 359-366. doi: 10.1016/j.fct.2013.07.021
20. Carrizzo, A., Puca, A., Damato, A., Marino, M., Franco, E., Pompeo, F., et al. (2013b). Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 62, 359-366. doi: 10.1161/HYPERTENSIONAHA.111.01009
21. Cavasin, M. A., Yang, X. P., Liu, Y. H., Mehta, D., Karumanchi, R., Bulagannawar, M., et al. (2000). Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure. J. Cardiovasc. Pharmacol. 36, 472-480. doi: 10.1097/00005344-200010000-00009
22. Cerqueira, F. M., Brandizzi, L. I., Cunha, F. M., Laurindo, F. R., and Kowaltowski, A. J. (2012). Serum from calorie-restricted rats activates vascular cell eNOS through enhanced insulin signaling mediated by adiponectin. PLoS ONE 7:e31155. doi: 10.1371/journal.pone.0031155
23. Chowienczyk, P. J., Watts, G. F., Cockcroft, J. R., and Ritter, J. M. (1992). Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 340, 1430-1432. doi: 10.1016/0140-6736(92)92621-L
24. Clark, B. J., and Bertholet, A. (1983). Effects of pindolol on vascular smooth muscle. Gen. Pharmacol. 14, 117-119. doi: 10.1016/0306-3623(83)90078-2
25. Cockcroft, J. R., Chowienczyk, P. J., Brett, S. E., Chen, C. P., Dupont, A. G., Van Nueten, L., et al. (1995). Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J. Pharmacol. Exp. Ther. 274, 1067-1071.
26. Colucci, W. S., Kolias, T. J., Adams, K. F., Armstrong, W. F., Ghali, J. K., Gottlieb, S. S., et al., (2007). Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial. Circulation 116, 49-56. doi: 10.1161/CIRCULATIONAHA.106.666016
27. Conti, V., Corbi, G., Russomanno, G., Simeon, V., Ferrara, N., Filippelli, W., et al. (2012a). Oxidative stress effects on endothelial cells treated with different athletes' sera. Med. Sci. Sports Exerc. 44, 39-49. doi: 10.1249/MSS.0b013e318227f69c
28. Conti, V., Russomanno, G., Corbi, G., and Filippelli, A. (2012b). Exercise training in aging and diseases. Transl. Med. UniSa. 3, 74-80.
29. Conti, V., Russomanno, G., Corbi, G., Guerra, G., Grasso, C., Filippelli, W., et al. (2013). Aerobic training workload affects human endothelial cells redox homeostasis. Med. Sci. Sports Exerc. 45, 644-653. doi: 10.1249/MSS.0b013e318279fb59
30. Corbi, G., Conti, V., Russomanno, G., Rengo, G., Vitulli, P., Ciccarelli, A. L., et al. (2012). Is physical activity able to modify oxidative damage in cardiovascular aging? Oxid. Med. Cell. Longev. 2012, 728547. doi: 10.1155/2012/728547
31. Davel, A. P., Ceravolo, G. S., Wenceslau, C. F., Carvalho, M. H., Brum, P. C., and Rossoni, L. V. (2012). Increased vascular contractility and oxidative stress in ß2-adrenoceptor knockout mice: the role of NADPH oxidase. J. Vasc. Res. 49, 342-352. doi: 10.1159/000337486
32. Davel, A. P., Kawamoto, E. M., Scavone, C., Vassallo, D. V., and Rossoni, L. V. (2006). Changes in vascular reactivity following administration of isoproterenol for 1 week: a role for endothelial modulation. Br. J. Pharmacol. 148, 629-639. doi: 10.1038/sj.bjp.0706749
33. Dawes, M., Chowienczyk, P. J., and Ritter, J. M. (1997). Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by beta-adrenergic agonists in human forearm. Circulation 95, 2293-2297. doi: 10.1161/01.CIR.95.9.2293
34. Dessy, C., Moniotte, S., Ghisdal, P., Havaux, X., Noirhomme, P., and Balligand, J. L. (2004). Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 110, 948-954. doi: 10.1161/01.CIR.0000139331.85766.AF
35. Dessy, C., Saliez, J., Ghisdal, P., Daneau, G., Lobysheva, I. I., Frérart, F., et al. (2005). Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 112, 1198-1205. doi: 10.1161/CIRCULATIONAHA.104.532960
36. Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., and Zeiher, A. M. (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399, 601-605. doi: 10.1038/21224
37. Doggrell, S. A. (1990). Relaxant and beta 2-adrenoceptor blocking activities of (+/-)-, (+)- and (-)-pindolol on the rat isolated aorta. J. Pharm. Pharmacol. 42, 444-446. doi: 10.1111/j.2042-7158.1990.tb06590.x
38. Fargin, A., Raymond, J. R., Lohse, M. J., Kobilka, B. K., Caron, M. G., and Lefkowitz, R. J. (1998). The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 335, 358-360. doi: 10.1038/335358a0
39. Femminella, G. D., Rengo, G., Pagano, G., de Lucia, C., Komici, K., Parisi, V., et al. (2013). ß-adrenergic receptors and G protein-coupled receptor kinase-2 in Alzheimer's disease: a new paradigm for prognosis and therapy? J. Alzheimers Dis. 34, 341-347. doi: 10.3233/JAD-121813
40. Ferrara, N., Rinaldi, B., Corbi, G., Conti, V., Stiuso, P., Boccuti, S., et al. (2008). Exercise training promotes SIRT1 activity in aged rats. Rejuvenation Res. 11, 139-150. doi: 10.1089/rej.2007.0576
41. Ferro, A., Queen, L. R., Priest, R. M., Xu, B., Ritter, J. M., Poston, L., et al. (1999). Activation of nitric oxide synthase by beta 2-adrenoceptors in human umbilical vein endothelium in vitro. Br. J. Pharmacol. 126, 1872-1880. doi: 10.1038/sj.bjp.0702512
42. Fleming, I., and Busse, R. (2003). Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1-R12.
43. Förstermann, U., and Sessa, W. C. (2012). Nitric oxide synthases: regulation and function. Eur. Heart. J. 33, 829-837. doi: 10.1093/eurheartj/ehr304
44. Fratta Pasini, A., Garbin, U., Nava, M. C., Stranieri, C., Davoli, A., Sawamura, T., et al. (2005). Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J. Hypertens. 23, 589-596. doi: 10.1097/01.hjh.0000160216.86597.ff
45. Garovic, V. D., Joyner, M. J., Dietz, N. M., Boerwinkle, E., and Turner, S. T. (2003). Beta(2)-adrenergic receptor polymorphism and nitric oxide-dependent forearm blood flow responses to isoproterenol in humans. J. Physiol. 546(Pt 2), 583-589. doi: 10.1113/jphysiol.2002.031138
46. Graves, J., and Poston, L. (1993). Beta-adrenoceptor agonist mediated relaxation of rat isolated resistance arteries: a role for the endothelium and nitric oxide. Br. J. Pharmacol. 108, 631-637. doi: 10.1111/j.1476-5381.1993.tb12853.x
47. Green, D. J., Maiorana, A., O'Driscoll, G., and Taylor, R. (2004). Effect of exercise training on endothelium-derived nitric oxide function in humans. J. Physiol. 561(Pt 1), 1-25. doi: 10.1113/jphysiol.2004.068197
48. Green, S. A., Cole, G., Jacinto, M., Innis, M., and Liggett, S. B. (1993). A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. 268(31), 23116-23121.
49. Horackova, M., Armour, J. A., Hopkins, D. A., and Huang, M. H. (1995). Nitric oxide modulates signaling between cultured adult peripheral cardiac neurons and cardiomyocytes. Am. J. Physiol. 269(Pt 1), C504-C510.
50. Hutchinson, P. J., Palmer, R. M., and Moncada, S. (1987). Comparative pharmacology of EDRF and nitric oxide on vascular strips. Eur. J. Pharmacol. 141, 445-451. doi: 10.1016/0014-2999(87)90563-2
51. Ignarro, L. J. (2004). Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker. Blood Press. Suppl. 1, 2-16. doi: 10.1080/08038020410016557
52. Jáchymová, M., Horkỳ, K., Bultas, J., Kozich, V., Jindra, A., Peleska, J., et al. (2001). Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy. Biochem. Biophys. Res. Commun. 284, 426-430. doi: 10.1006/bbrc.2001.5007
53. Janssens, S., Pokreisz, P., Schoonjans, L., Pellens, M., Vermeersch, P., Tjwa, M., et al. (2004). Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ. Res. 94, 1256-1262. doi: 10.1161/01.RES.0000126497.38281.23
54. Jenkins, N. T., Padilla, J., Rector, S., and Laughlin, M. H. (2013). Influence of regular physical activity and caloric restriction on ß-adrenergic and natriuretic peptide receptor expression in retroperitoneal adipose tissue of OLETF rats. Exp. Physiol. doi: 10.1113/expphysiol.2013.074658. [Epub ahead of print].
55. Johnson, J. A., and Terra, S. G. (2002). Beta-adrenergic receptor polymorphisms: cardiovascular disease associations and pharmacogenetics. Pharm. Res. 19, 1779-1787. doi: 10.1023/A:1021477021102
56. Jones, S. P., Greer, J. J., van Haperen, R., Duncker, D. J., de Crom, R., and Lefer, D. J. (2003). Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice. Proc. Natl. Acad. Sci. U.S.A. 100, 4891-4896. doi: 10.1073/pnas.0837428100
57. Keating, G. M., and Jarvis, B. (2003). Carvedilol: a review of its use in chronic heart failure. Drugs. 63, 1697-1741. doi: 10.2165/00003495-200363160-00006
58. Landmesser, U., Engberding, N., Bahlmann, F. H., Schaefer, A., Wiencke, A., Heineke, A., et al. (2004). Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110, 1933-1939. doi: 10.1161/01.CIR.0000143232.67642.7A
59. Laurent, M., Daline, T., Malika, B., Fawzi, O., Philippe, V., Benoit, D., et al. (2009). Training-induced increase in nitric oxide metabolites in chronic heart failure and coronary artery disease: an extra benefit of water-based exercises? Eur. J. Cardiovasc. Prev. Rehabil. 16, 215-221. doi: 10.1097/HJR.0b013e3283292fcf
60. Leeson, C. P., Hingorani, A. D., Mullen, M. J., Jeerooburkhan, N., Kattenhorn, M., Cole, T. J., et al. (2002). Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ. Res. 90, 1153-1158. doi: 10.1161/01.RES.0000020562.07492.D4
61. Lembo, G., Iaccarino, G., Vecchione, C., Barbato, E., Izzo, R., Fontana, D., et al. (1997). Insulin modulation of an endothelial nitric oxide component present in the alpha2- and beta-adrenergic responses in human forearm. J. Clin. Invest. 100, 2007-2014. doi: 10.1172/JCI119732
62. Lembo, G., Vecchione, C., Izzo, R., Fratta, L., Fontana, D., Marino, G., et al. (2000). Noradrenergic vascular hyper-responsiveness in human hypertension is dependent on oxygen free radical impairment of nitric oxide activity. Circulation. 102, 552-557. doi: 10.1161/01.CIR.102.5.552
63. Leosco, D., Rengo, G., Iaccarino, G., Golino, L., Marchese, M., Fortunato, F., et al. (2008). Exercise promotes angiogenesis and improves beta-adrenergic receptor signalling in the post-ischaemic failing rat heart. Cardiovasc. Res. 78, 385-394. doi: 10.1093/cvr/cvm109
64. Levy, A. S., Chung, J. C., Kroetsch, J. T., and Rush, J. W. (2009). Nitric oxide and coronary vascular endothelium adaptations in hypertension. Vasc. Health Risk Manag. 5, 1075-1087.
65. Libby, P., Ridker, P. M., and Maseri, A. (2002). Inflammation and atherosclerosis. Circulation 105, 1135-1143. doi: 10.1161/hc0902.104353
66. Linke, A., Erbs, S., and Hambrecht, R. (2008). Effects of exercise training upon endothelial function in patients with cardiovascular disease. Front. Biosci. 13, 424-432. doi: 10.2741/2689
67. Liu, Y. H., Xu, J., Yang, X. P., Yang, F., Shesely, E., and Carretero, O. A. (2002). Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension. 39(Pt 2):375-381. doi: 10.1161/hy02t2.102796
68. Lyons, D. (1997). Impairment and restoration of nitric oxide-dependent vasodilation in cardiovascular disease. Int. J. Cardiol. 62(Suppl. 2), S101-S109. doi: 10.1016/S0167-5273(97)00247-7
69. Maffei, A., Vecchione, C., Aretini, A., Poulet, R., Bettarini, U., Gentile, M. T., et al. (2006). Characterization of nitric oxide release by nebivolol and its metabolites. Am. J. Hypertens. 19, 579-586. doi: 10.1016/j.amjhyper.2005.09.021
70. Marciano, C., Galderisi, M., Gargiulo, P., Acampa, W., D'Amore, C., Esposito, R., et al. (2012). Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. Eur. J. Nucl. Med. Mol. Imaging. 39, 1199-1206. doi: 10.1007/s00259-012-2117-9
71. McNamara, D. M., MacGowan, G. A., and London, B. (2002). Clinical importance of beta-adrenoceptor polymorphisms in cardiovascular disease. Am. J. Pharmacogenomics 2, 73-78. doi: 10.2165/00129785-200202020-00001
72. Molenaar, P., Malta, E., Jones, C. R., Buxton, B. F., and Summers, R. J. (1988). Autoradiographic localization and function of beta-adrenoceptors on the human internal mammary artery and saphenous vein. Br. J. Pharmacol. 95, 225-233. doi: 10.1111/j.1476-5381.1988.tb16568.x
73. Moncada, S. (1994). Nitric oxide. J. Hypertens. Suppl. 12, S35-S39.
74. Moniotte, S., Kobzik, L., Feron, O., Trochu, J. N., Gauthier, C., and Balligand, J. L. (2001). Upregulation of beta(3)-adrenoceptors and altered contractile response to inotropic amines in human failing myocardium. Circulation 103, 1649-1655. doi: 10.1161/01.CIR.103.12.1649
75. Montesanto, A., Crocco, P., Tallaro, F., Pisani, F., Mazzei, B., Mari, V., et al. (2013). Common polymorphisms in nitric oxide synthase (NOS) genes influence quality of aging and longevity in humans. Biogerontology 14, 177-186. doi: 10.1007/s10522-013-9421-z
76. Nair, A. P., Timoh, T., and Fuster, V. (2012). Contemporary medical management of systolic heart failure. Circ. J. 76, 268-277. doi: 10.1253/circj.CJ-11-1424
77. Nathan, C. (1992). Nitric oxide as a secretory product of mammalian cells. FASEB J. 6, 3051-3064.
78. Nathan, C. (1995). Natural resistance and nitric oxide. Cell. 82, 873-876. doi: 10.1016/0092-8674(95)90019-5
79. Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., et al. (2005). Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS. Science 310, 314-317. doi: 10.1126/science.1117728
80. Oriowo, M. A. (1995). Different atypical beta-adrenoceptors mediate isoprenaline-induced relaxation in vascular and non-vascular smooth muscles. Life Sci. 56, PL269-PL275. doi: 10.1016/0024-3205(95)00076-3
81. Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N. Engl. J. Med. 334, 1349-1355. doi: 10.1056/NEJM199605233342101
82. Palmer, R. M., Ferrige, A. G., and Moncada, S. (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526. doi: 10.1038/327524a0
83. Priest, R. M., Hucks, D., and Ward, J. P. (1997). Noradrenaline, beta-adrenoceptor mediated vasorelaxation and nitric oxide in large and small pulmonary arteries of the rat. Br. J. Pharmacol. 122, 1375-1384. doi: 10.1038/sj.bjp.0701528
84. Puca, A. A., Carrizzo, A., Villa, F., Ferrario, A., Casaburo, M., Maciag, A., et al. (2013). Vascular ageing: the role of oxidative stress. Int. J. Biochem. Cell. Biol. 45, 556-559. doi: 10.1016/j.biocel.2012.12.024
85. Queen, L. R., Ji, Y., Xu, B., Young, L., Yao, K., Wyatt, A. W., et al. (2006). Mechanisms underlying beta2-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells. J. Physiol. 576(Pt 2), 585-594. doi: 10.1113/jphysiol.2006.115998
86. Recchia, F. A., McConnell, P. I., Bernstein, R. D., Vogel, T. R., Xu, X., and Hintze, T. H. (1998). Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ. Res. 83, 969-979. doi: 10.1161/01.RES.83.10.969
87. Reihsaus, E., Innis, M., MacIntyre, N., and Liggett, S. B. (1993). Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell. Mol. Biol. 8, 334-339. doi: 10.1165/ajrcmb/8.3.334
88. Rengo, G., Cannavo, A., Liccardo, D., Zincarelli, C., de Lucia, C., Pagano, G., et al. (2013a). Vascular endothelial growth factor blockade prevents the beneficial effects of ß-blocker therapy on cardiac function, angiogenesis and remodeling in heart failure. Circ. Heart. Fail. doi: 10.1161/CIRCHEARTFAILURE.113.000329. [Epub ahead of print].
89. Rengo, G., Pagano, G., Squizzato, A., Moja, L., Femminella, G. D., de Lucia, C., et al. (2013b). Oral anticoagulation therapy in heart failure patients in sinus rhythm: a systematic review and meta-analysis. PLoS ONE 8:e52952. doi: 10.1371/journal.pone.0052952
90. Rengo, G., Leosco, D., Zincarelli, C., Marchese, M., Corbi, G., Liccardo, D., et al. (2010). Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. Am. J. Physiol. Heart Circ. Physiol. 298, H2032-2038. doi: 10.1152/ajpheart.00702.2009
91. Rengo, G., Lymperopoulos, A., Zincarelli, C., Femminella, G., Liccardo, D., Pagano, G., et al. (2012a). Blockade of ß-adrenoceptors restores the GRK2-mediated adrenal a(2) -adrenoceptor-catecholamine production axis in heart failure. Br. J. Pharmacol. 166, 2430-2440. doi: 10.1111/j.1476-5381.2012.01972.x
92. Rengo, G., Perrone-Filardi, P., Femminella, G. D., Liccardo, D., Zincarelli, C., de Lucia, C., et al. (2012b). Targeting the ß-adrenergic receptor system through G-protein-coupled receptor kinase 2: a new paradigm for therapy and prognostic evaluation in heart failure: from bench to bedside. Circ. Heart Fail. 5, 385-391. doi: 10.1161/CIRCHEARTFAILURE.112.966895
93. Rengo, G., Zincarelli, C., Femminella, G. D., Liccardo, D., Pagano, G., de Lucia, C., et al. (2012c). Myocardial ß(2) -adrenoceptor gene delivery promotes coordinated cardiac adaptive remodelling and angiogenesis in heart failure. Br. J. Pharmacol. 166, 2348-2361. doi: 10.1111/j.1476-5381.2012.01954.x
94. Rinaldi, B., Corbi, G., Boccuti, S., Filippelli, W., Rengo, G., Leosco, D., et al. (2006). Exercise training affects age-induced changes in SOD and heat shock protein expression in rat heart. Exp. Gerontol. 41, 764-770. doi: 10.1016/j.exger.2006.05.008
95. Rush, J. W., Denniss, S. G., and Graham, D. A. (2005). Vascular nitric oxide and oxidative stress: determinants of endothelial adaptations to cardiovascular disease and to physical activity. Can. J. Appl. Physiol. 30, 442-474. doi: 10.1139/h05-133
96. Salazar, N. C., Vallejos, X., Siryk, A., Rengo, G., Cannavo, A., Liccardo, D., et al. (2013). GRK2 blockade with betaARKct is essential for cardiac beta2-adrenergic receptor signaling towards increased contractility. Cell. Commun. Signal. 11, 64. doi: 10.1186/1478-811X-11-64
97. Savvidou, M. D., Vallance, P. J., Nicolaides, K. H., and Hingorani, A. D. (2001). Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension. 38, 1289-1293. doi: 10.1161/hy1201.097305
98. Scherrer-Crosbie, M., Ullrich, R., Bloch, K. D., Nakajima, H., Nasseri, B., Aretz, H. T., et al. (2001). Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 104, 1286-1291. doi: 10.1161/hc3601.094298
99. Schwarz, P., Diem, R., Dun, N. J., and Förstermann, U. (1995). Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res. 77, 841-848. doi: 10.1161/01.RES.77.4.841
100. Selemidis, S., Dusting, G. J., Peshavariya, H., Kemp-Harper, B. K., and Drummond, G. R. (2007). Nitric oxide suppresses NADPH oxidase-dependent superoxide production by S-nitrosylation in human endothelial cells. Cardiovasc. Res. 75, 349-358. doi: 10.1016/j.cardiores.2007.03.030
101. Stary, H. C., Chandler, A. B., Glagov, S., Guyton, J. R., Insull, W. Jr., Rosenfeld, M. E., et al. (1994). A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 89, 2462-2478. doi: 10.1161/01.CIR.89.5.2462
102. Sun, D., Huang, A., Zhao, G., Bernstein, R., Forfia, P., Xu, X., et al. (2000). Reduced NO-dependent arteriolar dilation during the development of cardiomyopathy. Am. J. Physiol. Heart. Circ. Physiol. 278, H461-H468.
103. Taimeh, Z., Loughran, J., Birks, E. J., and Bolli, R. (2013). Vascular endothelial growth factor in heart failure. Nat. Rev. Cardiol. 10, 519-530. doi: 10.1038/nrcardio.2013.94
104. Taylor, M. R., and Bristow, M. R. (2004). The emerging pharmacogenomics of the beta-adrenergic receptors. Congest. Heart. Fail. 10, 281-288. doi: 10.1111/j.1527-5299.2004.02019.x
105. Tesauro, M., Thompson, W. C., Rogliani, P., Qi, L., Chaudhary, P. P., and Moss, J. (2000). Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc. Natl. Acad. Sci. U.S.A. 97, 2832-2835. doi: 10.1073/pnas.97.6.2832
106. Timmermann, B., Mo, R., Luft, F. C., Gerdts, E., Busjahn, A., Omvik, P., et al. (1998). Beta-2 adrenoceptor genetic variation is associated with genetic predisposition to essential hypertension: the Bergen Blood Pressure Study. Kidney Int. 53, 1455-1460. doi: 10.1046/j.1523-1755.1998.00926.x
107. Toblli, J. E., DiGennaro, F., Giani, J. F., and Dominici, F. P. (2012). Nebivolol: impact on cardiac and endothelial function and clinical utility. Vasc. Health Risk Manag. 8, 151-160. doi: 10.2147/VHRM.S20669
108. Trochu, J. N., Leblais, V., Rautureau, Y., Bévérelli, F., Le Marec, H., and Berdeaux, A., et al. (1999). Beta 3-adrenoceptor stimulation induces vasorelaxation mediated essentially by endothelium-derived nitric oxide in rat thoracic aorta. Br. J. Pharmacol. 128, 69-76. doi: 10.1038/sj.bjp.0702797
109. Troost, R., Schwedhelm, E., Rojczyk, S., Tsikas, D., and Frölich, J. C. (2000). Nebivolol decreases systemic oxidative stress in healthy volunteers. Br. J. Clin. Pharmacol. 50, 377-379. doi: 10.1046/j.1365-2125.2000.00258.x
110. Tulis, D. A. (2008). Novel therapies for cyclic GMP control of vascular smooth muscle growth. Am. J. Ther. 15, 551-564. doi: 10.1097/MJT.0b013e318140052f
111. Tzemos, N., Lim, P. O., and MacDonald, T. M. (2001). Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 104, 511-514. doi: 10.1161/hc3001.094207
112. Vanhoutte, P. M., and Gao, Y. (2013). Beta blockers, nitric oxide, and cardiovascular disease. Curr. Opin. Pharmacol. 13, 265-273. doi: 10.1016/j.coph.2012.12.002
113. Vecchione, C., Aretini, A., Marino, G., Bettarini, U., Poulet, R., Maffei, A., et al. (2006). Selective Rac-1 inhibition protects from diabetes-induced vascular injury. Circ. Res. 98, 218-225. doi: 10.1161/01.RES.0000200440.18768.30
114. Wiemer, G., Itter, G., Malinski, T., and Linz, W. (2001). Decreased nitric oxide availability in normotensive and hypertensive rats with failing hearts after myocardial infarction. Hypertension 38, 1367-1371. doi: 10.1161/hy1101.096115
115. Wojciechowski, D., and Papademetriou, V. (2008). Beta-blockers in the management of hypertension: focus on nebivolol. Expert. Rev. Cardiovasc. Ther. 6, 471-479. doi: 10.1586/14779072.6.4.471
116. Wu, K. K. (2002). Regulation of endothelial nitric oxide synthase activity and gene expression. Ann. N.Y. Acad. Sci. 962, 122-130. doi: 10.1111/j.1749-6632.2002.tb04062.x
117. Wyatt, A. W., Steinert, J. R., Wheeler-Jones, C. P., Morgan, A. J., Sugden, D., Pearson, J. D., et al. (2002). Early activation of the p42/p44MAPK pathway mediates adenosine-induced nitric oxide production in human endothelial cells: a novel calcium-insensitive mechanism. FASEB J. 16, 1584-1594. doi: 10.1096/fj.01-0125com
118. Yang, H. T., Prior, B. M., Lloyd, P. G., Taylor, J. C., Li, Z., Laughlin, M. H., et al. (2008). Training-induced vascular adaptations to ischemic muscle. J. Physiol. Pharmacol. 59(Suppl. 7), 57-70.
119. Yetik-Anacak, G., and Catravas, J. D. (2006). Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul. Pharmacol. 45, 268-276. doi: 10.1016/j.vph.2006.08.002
120. Zhang, X., Lynch, A. I., Davis, B. R., Ford, C. E., Boerwinkle, E., Eckfeldt, J. H., et al. (2012). Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study. PLoS ONE 7:e34217. doi: 10.1371/journal.pone.0034217